COVID-19–induced olfactory loss - 05/04/23

Doi : 10.1016/j.jaci.2023.02.007

Boris A. Stuck, MD ^a,^⁎ , Susanne Menzel, MD ^b, Martin Laudien, MD ^c, Constantin A. Hintschich, MD ^d, Thomas Hummel, MD ^b
^a Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany
^b Smell and Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Dresden, Germany
^c Department of Otorhinolaryngology, Head and Neck Surgery, Kiel University, University Medical Centre Schleswig-Holstein, Kiel, Germany
^d Department of Otorhinolaryngology, Regensburg University Hospital, Regensburg, Germany

^∗Corresponding author: Boris A. Stuck, MD, Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Baldingerstraße, 35043 Marburg, Germany.Department of OtorhinolaryngologyHead, and Neck SurgeryUniversity Hospital MarburgPhilipps-Universität MarburgBaldingerstraßeMarburg35043Germany

Le texte complet de cet article est disponible en PDF.

connectez-vous ou créez un compte

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Key words : Hyposmia, anosmia, smell, corona virus, SARS

Le texte complet de cet article est disponible en PDF.

Plan

Prevalence of COVID-19–induced OD

Mechanisms of COVID-19–induced OD

Time course of OD in COVID-19

Treatment options for COVID-19–induced OD

Conclusion

Disclosure of potential conflict of interest: In the past 5 years, M. Laudien has engaged in cooperation with Olympus Deutschland GmbH, Olympus Europa SE and Co KG, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Brainlab Sales GmbH, GlaxoSmithKline GmbH and Co KG, and the John Grube Foundation. B. A. Stuck has received research grants, reimbursement of travel expenses, and speaking fees from GlaxoSmithKlinie GmbH and Co KG, Merck, and Sanofi; in addition, his department has received financial support for meetings or symposia from Bristol-Myers Squibb, Merck, Neuwirth Medical Products, ALK, Sanofi, Pohl-Boskamp, MSD, and Takeda. In the past 5 years, T. Hummel has engaged in cooperation with Sony (Stuttgart, Germany), Smell and Taste Lab (Geneva, Switzerland), Takasago (Paris, France), aspUraclip (Berlin, Germany), Baia Foods (Madrid, Spain), Bayer (Berlin, Germany), Procter and Gamble (London, United Kingdom) Burghart (Wedel, Germany), and Primavera (Oy-Mittelberg, Germany). The rest of the authors declare that they have no relevant conflicts of interest.